Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice
- Ahern, Elizabeth
- Harjunpaa, Heidi
- Barkauskas, Deborah
- Allen, Stacey
- Takeda, Kazuyoshi
- Yagita, Hideo
- Wyld, David
- Dougall, William C.
- Teng, Michele W. L.
- Smyth, Mark J.
Publication date
October 2017
DOI Publisher
American Association for Cancer Research (AACR) ISSN
1078-0432Abstract
Purpose: Novel partners for established immune checkpoint inhibitors in the treatment of cancer are needed to address the problems of primary and acquired resistance. The efficacy of combination RANKL and CTLA4 blockade in antitumor immunity has been suggested by recent case reports in melanoma. Here, we provide a rationale for this combination in mouse models of cancer
Add to ORKG